Discrepancies between the molecular characteristics of the primary tumor and CTCs are targets of interest in a randomized phase II trial for patients with HER2-negative primary breast cancer, who after completing (neo)adjuvant chemotherapy and surgery, have detectable CTCs in their peripheral blood. This evidence concerns the gene ERBB2 and breast carcinoma.